BIMI Holdings Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical solution, and pharmaceutical and other healthcare products in the People's Republic of China and the United States. The company operates through four segments: Medical Devices; Healthcare Products; Wholesale Pharmaceuticals; and Pharmacy Retail. The Pharmacy Retail segment offers prescription and OTC medicines; TCM; healthcare supplies; traditional Chinese medicines; and sundry items. The Wholesale Pharmaceuticals segment provides prescription; OTC medicines; TCM; healthcare supplies; and sundry items. The Medical Device segment distributes medical devices, including medical consumables. The Healthcare products segment offers dietary supplements comprising cardiovascular products; anti-insomnia and depression products; male aphrodisiac products; menopausal syndrome products; gout products; and immunity products. It sells its products through pharmacies; retail stores; private and government clinics; directly owned stores; third party pharmacies; hospitals; drug wholesalers; and medical device dealers. The company was formerly known as BIMI International Medical Inc. and changed its name to BIMI Holdings Inc. in January 2024. The company was incorporated in 2000 and is based in New York, New York.
0 transactions — 0 buys and 0 sales reported by BIMI Holdings Inc. executives.
0 institutional funds report a position on BIMI in their latest SEC quarterly filing.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of BIMI on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year